
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is expected to see continued strong growth in its immunology business, driven by strong script growth for Skyrizi and Rinvoq. However, the company faces pricing pressures that could negatively affect margins. Investor concerns regarding competition and potential LOEs are overblown, and their diverse portfolio and strong pipeline differentiate them from other pharmaceutical companies facing similar challenges.
Bears say
AbbVie is facing multiple risks that could negatively impact their financial performance and earnings growth, including increasing competition in the immunology market and potential negative pipeline trial results. The recent acquisitions of Cerevel and ImmunoGen may not be enough to offset any potential challenges in their base business. The company's high valuation and reliance on key products such as Skyrizi and Rinvoq also pose a risk if their market share is impacted.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares